Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Ponatinib Second-Line Therapy in Chronic Phase CML
2016-000618-30Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by GWT-TUD. Primary endpoint: Major molecular response by 12 months. Started Jun 2018; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2016-000618-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000618-30.